Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice

Background Atypical antipsychotic drugs have some efficacy in alleviating the negative and some cognitive symptoms of schizophrenia but those effects are small and mechanisms of this action are still unknown A few clinical reports have suggested that antidepressants (ADs), are able to augment the activity of atypical antipsychotic drugs. Thus, in the present study, we aimed to evaluate the effect of ADs, escitalopram (ESC) or mirtazapine (MIR) and aripiprazole (an atypical antipsychotic drug) given separately or jointly, on the MK-801-induced positive and cognitive symptoms of schizophrenia in mice. Methods The experiments were conducted on male Albino Swiss mice. ADs and aripiprazole were given 30 min before MK-801 injection. Locomotor hyperactivity induced by MK-801 (0.3 mg/kg) was measured for 30 min, starting 30 min after MK-801 administration. In the novel object recognition test, MK-801 (0.2 mg/kg) was given 30 min before the first introductory session. Memory retention was evaluated for 5 min, starting 90 min after the introductory session. Results Aripiprazole (0.3 mg/kg) reduced the locomotor hyperactivity induced by MK-801(0.3 mg/kg). Co-treatment with an inactive dose of aripiprazole and ESC or MIR inhibited the effect of MK-801. Moreover, MK-801 (0.2 mg/kg) decreased the memory retention. Aripiprazole (0.3 mg/kg) reversed that effect. Co-treatment with an inactive dose of aripiprazole and ESC or MIR abolished the deficit of object recognition memory induced by MK-801. Conclusions The obtained results suggest that ADs may enhance the antipsychotic-like effect of aripiprazole in the animal tests used for evaluation of some positive and cognitive symptoms of schizophrenia.

• Publication year

  2018

• Venue

  Pharmacological Reports

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.pharep.2018.02.022PMID 29885435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats

  2015cited by this paper
• The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.

  2014cited by this paper
• The effect of combined treatment with escitalopram and risperidone on the MK-801-induced changes in the object recognition test in mice

  2013cited by this paper
• Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.

  2013cited by this paper
• Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice

  2013cited by this paper
• Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice

  2012cited by this paper
• Augmentation by escitalopram, but not citalopram or R‐citalopram, of the effects of low‐dose risperidone: Behavioral, biochemical, and electrophysiological evidence

  2012cited by this paper
• Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents.

  2011cited by this paper
• Effects of S‐citalopram, citalopram, and R‐citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N‐methyl‐D‐aspartate receptor‐mediated transmission in the medial prefrontal cortex and cognitive function in the rat

  2011cited by this paper
• Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.

  2011cited by this paper
• The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.

  2010cited by this paper
• Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

  2010cited by this paper
• Mirtazapine

  2009cited by this paper
• Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats--a preliminary investigation.

  2008cited by this paper
• Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors

  2008cited by this paper
• The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice

  2007cited by this paper
• Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

  2007cited by this paper
• In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain

  2007cited by this paper
• The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

  2007cited by this paper
• Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

  2006cited by this paper
• Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats.

  2005cited by this paper
• Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex.

  2005cited by this paper
• Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action

  2005cited by this paper
• Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.

  2005cited by this paper
• Size of burden of schizophrenia and psychotic disorders.

  2005cited by this paper
• 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism.

  2004cited by this paper
• A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.

  2004cited by this paper
• Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.

  2004cited by this paper
• Identification of separable cognitive factors in schizophrenia.

  2004cited by this paper
• Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.

  2004cited by this paper
• Animal behavior models of the mechanisms underlying antipsychotic atypicality.

  2003cited by this paper
• Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

  2003cited by this paper
• Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

  2003cited by this paper
• ARIPIPRAZOLE: A REVIEW OF ITS PHARMACOLOGY AND CLINICAL USE

  2003cited by this paper
• The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.

  2002cited by this paper
• 5‐HT2A and D2 receptor blockade increases cortical DA release via 5‐HT1A receptor activation: a possible mechanism of atypical antipsychotic‐induced cortical dopamine release

  2001cited by this paper
• Neurobiology of schizophrenia

  2000cited by this paper
• Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

  1999cited by this paper
• Cellular colocalization of dopamine D1 and D2 receptors in rat medial prefrontal cortex

  1995cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Dopaminergic Terminals in the Rat Cortex

  1973cited by this paper

• Selective recognition memory impairment in mitochondrial hydroxylase Clk1 mutant mice, rescued by antipsychotics

  2025cites this paper
• Correlation between desynchrony of hippocampal neural activity and hyperlocomotion in the model mice of schizophrenia and therapeutic effects of aripiprazole

  2024cites this paper
• Paliperidone alleviates MK-801-induced damage to prefrontal cortical neurons via the PP2A/PTEN pathway.

  2022cites this paper
• Distribution of Aquaporin-4 channels in hippocampus and prefrontal cortex in mk-801-treated balb/c mice

  2022cites this paper
• Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice

  2022cites this paper
• Investigation of the protective effect of resveratrol in an MK-801-induced mouse model of schizophrenia

  2021cites this paper
• Down-regulation of N-methyl-D-aspartate receptor subunits 1 affects neurogenesis of hippocampal neural stem cells

  2021cites this paper
• Combination of MAP6 deficit, maternal separation and MK801 in female mice: A 3-hit animal model of neurodevelopmental disorder with cognitive deficits.

  2021cites this paper
• Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex.

  2020cites this paper
• Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats

  2019cites this paper
• A UPLC-MS/MS Assay for Simultaneous Determination of Two Antipsychotics and Two Antidepressants in Human Plasma and Its Application in Clinic.

  2019cites this paper